Intended Audience:  Healthcare Professionals including Obstetricians, Gynecologists, Physician Assistants, and Nurses specializing in Women's Health (NPs, APNs, CMs, and RNs); Primary Care Physicians and Family Medicine Practitioners, Managed Care professionals

Bayer TA Rationale for Educational Support:

• Educate health care professionals on the broad impact of menopause on women in both their personal and professional lives, including physical, emotional, and financial effects.
• Provide guidance on the identification, counseling, and management of women as they enter the menopausal transition.
• Expand awareness of the role of the hypothalamic KNDy system on vasomotor symptoms, sleep disorders, and mood disturbances.
• Impact of untreated menopause symptoms on chronic diseases (e.g., cardiovascular disease)

Preferred Format:

• Enduring
• Downloadable slides
• Incorporation of social media outreach (You-Tube, FaceBook, Spotify, LinkedIn, Twitter)
• Podcast
• Live Virtual

Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).
The proposal should include:

•Needs assessment
• Educational design and rationale for selection (where applicable)
•Learning Objectives
• Proposed Faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan
• Detailed budget (please use the template available on the website)

Provider Justification:

Copy of most recent accreditation letter and status

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:
• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References

1.Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health qual Life Outcomes 2005;3:47.
2.Whiteley J, et al. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J of Women’s Health 2013:22:983.
3.Dominus S. Women have been misled about menopause. New York times.  Published Feb 1, 2023. https://www.nytimes.com/2023/02/01/magazine/menopause-hot-flashes-hormone-therapy.html.
4.United States Census Bureau.  Population estimates (sex by age), 2008. http://factfinder2.census.gov.
5.Hill K. The demography of menopause. Maturatas 1996;23:113.
6.Nappi RE, Kroll R, Siddiqui E, et al.  Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden.  Menopause 2021;28:875.
7.Thurston RC, Chang Y, Buysse DJ, et al. Hot flashes and awakenings among midlife women. Sleep 2019;42:zsz131.
8. Williams RE, Kalilani L, Britt Dibenedtti D, et al. Frequency and severity of vasomotor symptoms among peri-and postmenopausal women in the United States. Climacteric 2008;11:32.
9.Freeman EW, Sammel MD, Lin H, et al. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011;117::1095. 
10.Woods NF , Hohensee C, Carpenter JS, et al. Symptom clusters among MsFLASH clinical trial participants. Menopause 2016;23:158.
11.NAMS Position Statement: The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767.
12.ACOG Practice Bulletin: Management of menopausal symptoms.  Number 141, Jan 2014 (reaffirmed 2018).
13.Crawford SL, Crandall CJ, Derby CA, et al. Menopausal hormone therapy trends before versus after 2002: impact of the Women’s Health Initiative study results.  Menopause 2018;26:588.
14.Optum Claims Data 2020: US VMS Patient Market Landscape, accessed January 2023.
15.Biglia N, Bounous VE, De Seta F, et al. Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update. Ecancermedicalscience 2019;13:909.
16.Orleans RJ, Li L, Kim M-J, et al. FDA approval of paroxetine for menopausal hot flushes. N Engl J Med 2014;370:1777.
17.Bayer Data on File. Source Symphony Health. Accessed April 2023.
18.Rance NE, Dacks PA, Mittleman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes.  Front Neuroendocrinol 2013;34:211.
19.Rance NE, Young WS 3rd. Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalamus of postmenopausal women.  Endocrinology 1991;128:2239.
20.Padilla SL, Johnson CW, Barker FD, et al. A neuronal circuit underlying the generation of hot flushes.  Cell Rep 2018;24:271.
21.Hrabovszky E, Borsay BA, Racz K, et al. Substance P immunoreactivity exhibits frequent colocalization with kisspeptin and neurokinin B in the human infundibular region.  PLoS One 2013;8:e72369.
22.Lieb K, Ahlvers K, Dancker K, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men.  Neuropsychopharmacology 2002;27:1041.
23.Simon JA, Anderson RA, Ballantyne E, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause 2023;30:239.
24.Modi M and Dhillo WS.  Neurokinin B and Neurokinin-3 receptor signaling: promising developments in the management of menopausal hot flushes. Semin Reprod Med 2019;37:125.
25.Christianson MS, Ducie JA, Altman K, et al. Menopause education: needs assessment of American obstetrics and gynecology residents.  Menopause 2013:20:1120.
26.Richard-Davis G, Singer A, King DD, Mattle L.  Understanding attitudes, beliefs, and behaviors surrounding menopause transition:results from three surveys.  Patient Related Outcome Measures 2022:13:273.